logo

With the rapid implementation of ‘targeted’ therapies, kidney cancer has entered a new era where old paradigms are being challenged, and new ones can be explored. The idea of deliv[...]
 Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study Abstract Objective To evaluate the ability of neoadjuvant axitinib to redu[...]
Every week the Editor-in-Chief selects the Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full art[...]
In this issue of BJU International, Johnson et al. [1] examine the association between neoadjuvant chemotherapy (NAC) for bladder cancer and 30-day morbidity related to radical cys[...]
Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity David C. Johnson*, Matthew E. Nielsen*†‡, Jonathan Matthews*†, Michael E. Woods*†, Eri[...]